37.54

0.20% 0.2425

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $37.54, with a volume of 334.68K. It is up +0.20% in the last 24 hours and up +3.62% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$37.30

Open:

$37.06

24h Volume:

334.68K

Relative Volume:

0.09

Market Cap:

$16.22B

Revenue:

$2.31B

Net Income/Loss:

$1.66B

P/E Ratio:

16.34

EPS:

2.297

Net Cash Flow:

$827.02M

1W Performance:

+2.65%

1M Performance:

+3.62%

6M Performance:

+13.64%

1Y Performance:

+37.41%

1-Day Range:

$36.76

$37.54

1-Week Range:

$36.23

$37.72

52-Week Range:

$24.05

$38.00

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1140)

Industry

Biotechnology (633)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2025-02-11

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	37.51	16.12B	2.31B	1.66B	827.02M	2.297
VRTX Vertex Pharmaceuticals Inc	418.71	109.22B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	641.73	67.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	426.77	57.35B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	837.91	50.87B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	185.93	39.72B	447.02M	-1.18B	-868.57M	-6.1812

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

08:07 AM

Royalty Pharma acquires AMVUTTRA royalty interest for $310 million - Investing.com

08:07 AM

07:21 AM

Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative

07:21 AM

07:17 AM

Royalty Pharma acquires AMVUTTRA royalty for $310 million - StreetInsider

07:17 AM

07:15 AM

Royalty Pharma (NASDAQ: RPRX) acquires 1% AMVUTTRA royalty for $310M from Blackstone - Stock Titan

07:15 AM

06:11 AM

Quantitative breakdown of Royalty Pharma plc recent moveTrade Signal Summary & Real-Time Stock Price Movement Reports - newser.com

06:11 AM

05:48 AM

Corton Capital Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat

05:48 AM

05:00 AM

Can Royalty Pharma plc stock rebound after recent weaknessEarnings Miss & Consistent Profit Trading Strategies - newser.com

05:00 AM

04:57 AM

Applying chart zones and confluence areas to Royalty Pharma plcMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com

04:57 AM

04:33 AM